Please login to the form below

Not currently logged in
Email:
Password:

Gentium

This page shows the latest Gentium news and features for those working in and with pharma, biotech and healthcare.

Jazz Pharma bags FDA approval for rare disease drug

Jazz Pharma bags FDA approval for rare disease drug

Jazz acquired Defitelio as part of its $1bn purchase of Italy's Gentium in 2013.

Latest news

  • Jazz offers $1bn for Italy's Gentium Jazz offers $1bn for Italy's Gentium

    Jazz offers $1bn for Italy's Gentium. Will gain access to recently-approved liver drug Defitelio. ... Shares in Nasdaq-listed Gentium closed just above $55.65 the day before the deal was announced.

  • Gentium expects EMA rejection for defibrotide Gentium expects EMA rejection for defibrotide

    Gentium expects EMA rejection for defibrotide. Negative feedback for drug’ s use in liver condition associated with stem cell transplantation. ... Gentium is expecting the European Medicines Agency (EMA) to turn down its investigational medicine

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics